Lower-Dose Leuprolide Approved for Advanced Prostate Cancer
New Hope for Prostate Cancer Patients: FDA Approves 3-Month Leuprolide Formulation The landscape of advanced prostate cancer treatment is evolving, and the recent FDA approval of a 3-month formulation of leuprolide mesylate (Camcevi ETM) offers a promising new option for patients. This long-acting injectable emulsion provides a convenient alternative to existing treatments, potentially improving adherence … Read more